Q-linea Ab · OMXSTO:QLINEA
Q-linea Ab — Q2 2020 Earnings Presentation
12 slides from Q-linea Ab's earnings presentation, 2020
Slide 1: Presentation Q2(20)
Presentation Q2(20) Jonas Jarvius, CEO Anders Lundin, CFO STRICTLY PRIVATE AND CONFIDENTIAL
Slide 2: Disclaimer
Disclaimer DISCLAIMER THIS PRESENTATION AND ITS CONTENTS ARE CONFIDENTIAL AND ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION IS
Slide 3: Q-linea in brief
Headquarters, Marketing and demo lab, Consumable production in Uppsala Q-linea in brief Lead product ASTar® Q-linea is developing disruptive solutions for faster infectious disease diagnostics, first product Introduction to the company targeting sepsis Active quarter together with Thermo Fisher Scie
Slide 4: Q-linea's lead product candidate – ASTar – a modular AST system
Q-linea’s lead product candidate – ASTar – a modular AST system • Phenotypic AST results in 3 to ASTar® offering 6 hours for blood System Rapid • Answer <45 minutes for e.g. urine • Fully automated • Up to 12 samples analyzed in Simple to use parallel Consumables • Up to 50 samples per 24h1) Fully-a
Slide 5: Key highlights second quarter
Key highlights second quarter Market presentation of ASTar on June 5th We presented ASTar in greater detail and demonstrated the easy workflow to start an analysis in ASTar First step towards launch for customers to familiarize with ASTar. Partnership with Thermo Fisher Scientific intensified The co
Slide 6: Key highlights second quarter
Key highlights second quarter Strong data on septic patients in pre-clinical study Prospective patient study performed together with Uppsala University Hospital. 17 patients sampled and analyzed with an antibiotic panel consisted of 29 antibiotic preparations for both fastidious and non-fastidious b
Slide 7: Key highlights second quarter
Key highlights second quarter Consumable design finalized Locked design for all consumables & packaging material First production batches for verification completed Verification testing ongoing In-house reference MIC testing Characterization has been completed for all isolates for the upcoming EU st
Slide 8: The effects of the Corona pandemic on Q-linea
The effects of the Corona pandemic on Q-linea So far, the effects have not caused a delay on Q-linea operations Most activities coupled to ASTar launch are still internal and new consumable production site in Uppsala operational. There is a strong interest from our clinical partners to perform studi
Slide 9: Income statement second quarter
Income statement second quarter Net sales in the second quarter amounted to SEK 0.1 million (0.5). Operating result totalled SEK -58.6 million (-44.5). The company reported a loss after tax of SEK -57.4 million (-44.0). Earnings per share, before and after dilution amounted to SEK -2.37 (-1.92). Fig
Slide 10: Balance sheet at end of second quarter
Balance sheet at end of second quarter Cash and cash equivalents amounted to SEK 38.0 million (26.0) Short-term investments in fixed-income funds SEK 235,4 million (150,4) and the current portion of non-current assets (listed bonds) SEK 95.1 million (30.1). Non-current assets, listed bonds SEK 90.4
Slide 11: Cash flow statement second quarter
Cash flow statement second quarter Cash flow from operating activities SEK -54.8 million (-40.9). Increased cash outflow from operating activities mainly due to a larger operating loss. Cash flow from investing activities SEK -190.3 millions (39.8). Cash surplus from direct issue were invested in sh
Slide 12: Thank you
Thank you Strictly private and confidential 12